重组人肿瘤坏死因子相关凋亡诱导配体蛋白(rhTRAIL) 逆转人肺腺癌细胞A549/ CDDP耐顺铂效应的初步研究

Reversing Effect of rhTRAIL on Cisplatin-resistant Human Lung Adenocarcinma Cell Line A549/ CDDP

摘要: 目的探讨重组人可溶性肿瘤坏死因子相关诱导配体蛋白(rhTRAIL)对人肺腺癌细胞A549／CDDP耐顺铂的逆转效应。方法以顺铂(CDDP)联合不同浓度的rhTRAIL处理A549／CDDP，以四氮唑噻蓝盐(MTT)比色法检测顺铂的半效抑制浓度IC50并计算耐药逆转倍数RI。结果 rhTRAIL体外可明显降低A549／CDDP对CDDP的IC50提高耐药逆转倍数。结论 rhTRAIL体外可较大程度逆转A549／CDDP细胞对CDDP的耐药性，有望成为抗耐药性肺癌的一种新的生物制剂。

Abstract: Objective 　To explore the reversal effect s of rhTRAIL on the multidrug-resistant cell line A549/ CDDP. Methods 　A549/ CDDP was treated with combinations of rhTRAIL. IC50 values and reversing drug-resistance index (RI) of the chemotherapeutic drug were analyzed by MTT assay. Results 　After treated with rhRRAIL, IC50 values of CDDP of A549/ CDDP cell line were reduced very significantly ( P < 0. 01), while RI augmented significantly ( P < 0. 05) . Conclusion 　rhTRAIL has reversal effects on multi-drug resistant cell line A549/ CDDP, which is a very promising biological drug for drug resistant lung cancer.